ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).

Authors

Myung-Ju Ahn

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Myung-Ju Ahn , Yufan Liu , Teresa Improta , Michelle Marcovitz , Kate DiPiazza , Mark C. Lanasa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.

First Author: Marina Chiara Garassino

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)

First Author: Tony Mok

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).

First Author: Ferdinandos Skoulidis

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).

First Author: Sarah Sammons